Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1996-7-18
pubmed:abstractText
The results of chemotherapy for patients with esophagogastric carcinoma have generally been modest but regimens developed more recently have produced higher response rates, and rekindled interest in neoadjuvant chemotherapy. One such regimen is epirubicin, cisplatin, and 5-fluorouracil (ECF). This study evaluates its efficacy, toxicity, impact on quality of life (QL), and impact on survival in a large consecutive series of patients with metastatic and locally advanced disease (LAD).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1978-85
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:8640659-Adenocarcinoma, pubmed-meshheading:8640659-Adult, pubmed-meshheading:8640659-Aged, pubmed-meshheading:8640659-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:8640659-Cisplatin, pubmed-meshheading:8640659-Combined Modality Therapy, pubmed-meshheading:8640659-Epirubicin, pubmed-meshheading:8640659-Esophageal Neoplasms, pubmed-meshheading:8640659-Esophagogastric Junction, pubmed-meshheading:8640659-Female, pubmed-meshheading:8640659-Fluorouracil, pubmed-meshheading:8640659-Follow-Up Studies, pubmed-meshheading:8640659-Humans, pubmed-meshheading:8640659-Infusions, Intravenous, pubmed-meshheading:8640659-Male, pubmed-meshheading:8640659-Middle Aged, pubmed-meshheading:8640659-Quality of Life, pubmed-meshheading:8640659-Stomach Neoplasms, pubmed-meshheading:8640659-Survival Analysis
pubmed:year
1996
pubmed:articleTitle
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
pubmed:affiliation
Cancer Research Campaign Section of Medicine, Institute of Cancer Research, Sutton, Surrey, UK.
pubmed:publicationType
Journal Article, Clinical Trial